Αρχειοθήκη ιστολογίου

Δευτέρα 12 Μαρτίου 2018

Response letter to the editor about the editorial by oppenheimer and greenberger “baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO” (2017;119:474-5)

alertIcon.gif

Publication date: Available online 12 March 2018
Source:Annals of Allergy, Asthma & Immunology
Author(s): Paul A. Greenberger, John j. Oppenheimer




http://ift.tt/2FHsTxQ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου